Article Detail - JE Part B
NCD 90.2: NGS for Medicare Beneficiaries with Germline (Inherited) Cancer
MLN Matters Number: MM11837
Related CR Release Date: September 11, 2020
Related CR Transmittal Number: R10346NCD
Related Change Request (CR) Number: 11837
Effective Date: January 27, 2020
Implementation Date: November 13, 2020
CR 11837 informs you about National Coverage Determination (NCD) 90.2, Next Generation Sequencing (NGS) for Medicare Beneficiaries with germline (inherited) cancer. Effective for dates of service on and after January 27, 2020, the Centers for Medicare & Medicaid Services (CMS) has determined that NGS, as a diagnostic laboratory test, is reasonable and necessary and covered nationally for patients with germline (inherited) cancer when performed in a CLIA-certified laboratory, when ordered by a treating physician, and when specific requirements are met. Make sure that your billing staffs are aware of these changes.
View the complete CMS Medicare Learning Network (MLN) Matters (MM)11837.
Last Updated Wed, 16 Sep 2020 15:33:06 +0000